期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 230, 期 2, 页码 259-271出版社
WILEY
DOI: 10.1002/jcp.24791
关键词
-
资金
- National Institutes of Health [P01 CA104177, R01 CA097318, R01 CA127641, R01 CA168517]
- Department of Defense synergy [W81XWH-10-PCRP-SIDA]
- National Cancer Institute [R01 CA138540-01A1]
- James S. McDonnell Foundation
Gene therapy, which involves replacement of a defective gene with a functional, healthy copy of that gene, is a potentially beneficial cancer treatment approach particularly over chemotherapy, which often lacks selectivity and can cause non-specific toxicity. Despite significant progress pre-clinically with respect to both enhanced targeting and expression in a tumor-selective manner several hurdles still prevent success in the clinic, including non-specific expression, low-efficiency delivery and biosafety. Various innovative genetic approaches are under development to reconstruct vectors/transgenes to make them safer and more effective. Utilizing cutting-edge delivery technologies, gene expression can now be targeted in a tissue-and organ-specific manner. With these advances, gene therapy is poised to become amenable for routine cancer therapy with potential to elevate this methodology as a first line therapy for neoplastic diseases. This review discusses recent advances in gene therapy and their impact on a pre-clinical and clinical level. (C) 2014 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据